RISE Research Inc. (“RISE”) and Luminor Medical Technologies Inc. (TSXV:LMT) (“Luminor”) are pleased to announce RISE’s comprehensive strategic partnership with Constance Therapeutics (“CT”), an established San Francisco-based developer and manufacturer of premium medical cannabis extract products for physician and patient use in California.
The partnership includes a distribution agreement that will see RISE build and manage a retail sales and distribution channel for both CT and RISE products in the California market. RISE will deploy a direct sales team in the state to sign top-tier dispensaries, augmented by a personalized support program for customers and patients to be delivered at the store level. RISE expects to create a network of at least 240 premium store locations in California within the next 12 months.
Leveraging its pharmaceutical grade product, know-how, and intellectual property (“IP”) assets, combined with RISE’s patent pending formulation, CT will produce a product line of sexual health and wellness products under license for RISE, to be sold in California. The product line will be developed at CT’s San Francisco lab and manufacturing headquarters and will be available in California retail channels in April 2018. Following the initial rollout, RISE plans to expand product sales to other U.S. states, as well as European markets.
“Validated science will be at the core of our product development,” said Anton Mattadeen, CEO of RISE. “Constance Therapeutics is a leader in creating cannabis-based extracts for use by physicians and patients. Their highly-controlled, patented extraction and formulation processes make them the ideal partner for RISE, as we are committed to evolving our intellectual property into tested and evaluated consumer products. This relationship with CT not only adds a strong foundation to support our entry into the California market, it also aligns us with one of the most trusted voices in the space. The value that Constance Finley brings to our partnership substantially advances our market position.”
“This partnership strengthens both companies at a critical juncture in the industry,” said Constance Finley, CEO and founder of Constance Therapeutics. “My company has led the industry in evidence-based medicinal cannabis products for a decade now, and with the rapid expansion occurring in the California market, we recognize the need for strategic partners that support one another while allowing each company to focus even more on its core competencies. CT’s new R&D and manufacturing lab in San Francisco will enable us to produce at a much greater capacity, while RISE is developing a comprehensive retail distribution and online marketing program that will give access to more patients clamoring for our products. I’m thrilled to be forging ahead with RISE as we secure a dominant position in this market.”
Update on Luminor’s Acquisition of RISE Research
On January 15, 2018, Luminor announced it had executed an agreement to acquire RISE. RISE shareholders have approved the acquisition and Luminor and RISE plan to close the transaction in the coming days.
About RISE Research Inc.
RISE Research Inc. is a private British Columbia Corporation that develops cutting-edge hemp and cannabis consumer products for the both medical and adult-use consumer market sectors.
About Constance Therapeutics
Constance Therapeutics is a vertically-integrated medicinal cannabis company producing standardized, science-based whole-plant cannabis extracts. These extracts fill the gap between traditional pharmaceuticals and commonplace cannabis products, providing much needed additional treatment options for physicians and their patients. Constance Therapeutics’ extracts are derived from fully trimmed, female, unfertilized cannabis flowers of plants with known genetics using certified organic, pharmaceutical-grade ethanol via a highly-controlled, quantitatively-defined and patented process based on solid scientific and engineering principles. Extracts are systematically third-party tested and routinely cross-tested in the industry’s most respected laboratories. Since 2008, the company has employed stringent, science-based processes and standards to ensure the highest quality and consistency. Headquartered in San Francisco, CA, Constance Therapeutics’ cannabis extracts have historically been available exclusively for therapeutic use by registered California patients under Proposition 215 and California Senate Bill 420. With the new California regulations, in addition to continuing to serve their physician referred medical patients, Constance Therapeutics will distribute their products throughout the state for sale in licensed dispensaries. Additionally, Constance Therapeutics is underway with globally licensing their patented formulations for sale in legal markets across the world. For further information, visit www.constancetherapeutics.com.
About Luminor Medical Technologies
Luminor Medical Technologies operates through two wholly owned subsidiaries: Scout Assessment Corp. and Jamaica BLU Limited. Scout Assessment Corp.’s key product is the Scout DS®, a device that has been regulatory cleared in certain markets as a non-invasive clinical tool to assist in the identification of both pre- and Type II diabetes. Jamaica BLU Limited holds the exclusive Canadian license for all current and future cannabis commercial products developed by RISE Research Inc. Currently, RISE Research’s portfolio consists of cannabis-based formulations to support adult sexual health and wellness.
For more information, please contact:
For RISE Research Inc. and Luminor Medical Technologies Inc.:
Mark Komonoski
Communications Director
mark@komonoski.com
877-255-8483
403-470-8384
For Constance Therapeutics:
Karissa Fowler // karissa@tatemfowler.com or Kate Tatem // kate@tatemfowler.com
Tatem Fowler Public Relations // (805) 419-0667
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. For a description of the risks and uncertainties facing Luminor and its business and affairs, readers should refer to Luminor’s Management’s Discussion and Analysis. Luminor undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change, unless required by law. The reader is cautioned not to place undue reliance on forward-looking information.
Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.
Click here to connect with Luminor Medical Technologies Inc. (TSXV:LMT) and receive an Investor Presentation. 

Source: www.newsfilecorp.com


Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today its participation in the following investor conferences:

  • Needham 2nd Annual Virtual Cannabis Conference – March 3 rd , 2021 – Management will participate in virtual one-on-one meetings.
  • 33rd Annual Roth Conference – March 15 th -17 th , 2021 – Charlie Bachtell, CEO and Co-Founder, will participate in a Fireside Chat and management will later participate in virtual one-on-one meetings on April 7 th .
  • Stifel Multi-Sector Conference – April 21 st , 2021 – Management will participate in virtual one-on-one meetings.

About Cresco Labs

Keep reading... Show less

Green Thumb Industries, a leading cannabis consumer packaged goods company and owner of Rise™ Dispensaries, is expanding key partnerships and creating scholarships earmarked for those from communities most impacted by the war on drugs as part of its corporate social responsibility program. The scholarships will be granted to a total of four students for programs at the Cleveland School of Cannabis in Ohio and Olive-Harvey College in Illinois. Additionally, Green Thumb will continue its support of Cabrini Green Legal Aid and partner with the North Lawndale Employment Network in Chicago as part of ongoing collaborations that include financial support, volunteerism and awareness initiatives.

Building on the foundation of Green Thumb’s LEAP initiative, which provided pro-bono support for social equity license applicants in Illinois and which will soon offer business incubator resources to newly awarded social equity entrepreneurs, these impactful partnerships mark a critical next step in prioritizing diversity, equity, and inclusion in the cannabis industry.

Keep reading... Show less

All five flavours of the Company’s KOIOS™ nootropic beverage product are now being carried by Jensen’s, a regional supermarket chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. This placement of KOIOS™ follows several other recent placements of the Company’s beverage products in regional supermarket chains across the United States as part of a strategy to passively build market share in specific geographical areas.

Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that the full range of five flavours of its KOIOS ™ nootropic beverages can now be purchased at all grocery stores operated by Jensen’s Foods (“Jensen’s”), a long-established family-owned grocery chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. In a press release dated February 19, 2021 the Company announced another chain-wide placement of KOIOS ™ nootropic beverages on the west coast of the United States with Market of Choice in Oregon. With this placement of KOIOS ™ in Jensen’s supermarkets, the Company’s beverage products are now carried in approximately 180 retail stores on the west coast, out of a total of more than 4,000 retail stores nationwide.

Keep reading... Show less

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) announces that Philip Young, CEO and Director, and Maghsoud Dariani, Chief Science Officer will be presenting on Thursday, February 25th, 2021 at 5:45 pm EST at “The Gold Standard in Psychedelic Investment, Psychedelic Capital Virtual Investment Conference”, a platform showcasing the top companies, latest IPOs, newest opportunities, and deepest industry insights.

As a presenting sponsor, the Company will connect directly with some of the earliest moving investors in the psychedelic industry and reach an audience of 2,000+ investors. Presentations are 30 minutes in length, with 10 minutes allocated to a one-on-one Q&A session with the audience.

Keep reading... Show less

As Canadian operators race to strengthen their positions in the cannabis landscape, are international pursuits outside North America still top of mind?

The role that mergers and acquisitions (M&A) have played in the expansion of Canadian companies across the globe has been monumental for the growth of the cannabis industry. Now the space has reached a critical point as the demands of the US market increase.

Keep reading... Show less